Elevated cholesterol levels: Benefit of ezetimibe is not proven

September 14, 2011 in Medications

Elevated blood cholesterol levels are regarded as a risk factor for heart attacks and other cardiovascular diseases. However, this does not necessarily mean that every cholesterol-lowering drug can also prevent heart attacks. For example, the benefit of the cholesterol-lowering drug ezetimibe is unclear. In particular, proof is lacking that patients have a greater benefit if they take ezetimibe in addition to statins for the prevention of heart attacks. This is the result of the final report published by the German Institute for Quality and Efficiency in Health Care (IQWiG) on 12 September 2011.

Prescribed largely in combination with statins

Ezetimibe is a cholesterol-absorption inhibitor. If taken orally, it acts in the by inhibiting the absorption of cholesterol into the body from ingested food, which leads to a reduction in blood . It is hoped that this also reduces the risk of . Ezetimibe is currently prescribed mainly in combination with a statin, which is also used for the prevention of heart attacks in certain patients. For specific statins, various studies have demonstrated that in such patients they not only levels but may also prevent heart attacks and other . Patients with elevated cholesterol levels who do not tolerate these drugs can also take ezetimibe without a statin.

IQWiG has now investigated whether ezetimibe - particularly in combination with statins - also lowers the risk of the complications mentioned.

Benefit of combination therapy not proven

A total of 2 studies were identified for the benefit assessment. In both studies, all patients received a statin as basic therapy. In the 24-month ENHANCE study, one half of the study participants additionally received ezetimibe, the others placebo. In the 14-month ARBITER-6-HALTS study, ezetimibe was compared with niacin (nicotinic acid). Relevant studies investigating ezetimibe as monotherapy were not available.

IQWiG analysed the results of the ENHANCE and ARBITER-6-HALTS studies particularly with regard to deaths, cardiovascular complications, health-related quality of life, and adverse effects. With regard to patient-relevant outcomes, neither of the 2 studies showed robust differences between the group of patients receiving ezetimibe plus a and the control group. In summary, the data provide no indication that ezetimibe shows more benefit or harm than niacin or placebo. However, the studies available so far are too small and too short to conclusively clarify the benefit and harm of this drug.

The attention of health care professionals is currently focused on an ongoing study (IMPROVE-IT). It is the first study with the primary aim of comparing the effect of simvastatin plus versus simvastatin plus placebo on cardiovascular outcomes. The study includes high-risk patients with acute coronary syndrome whose condition has already been stabilized. The results are expected in 2013.

Procedure of report production

IQWiG published the preliminary results in the form of the preliminary report at the beginning of May 2011 and interested parties were invited to submit comments. When the comments stage ended, the preliminary report was revised and sent as a final report to the contracting agency, the Federal Joint Committee, in July 2011. Only one written comment was received, which was published in a separate document at the same time as the final report. The report was produced in collaboration with external experts.

Provided by Institute for Quality and Efficiency in Health Care

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Merck ends development of Parkinson's disease drug

(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.

Medications created 16 hours ago | popularity 1 / 5 (1) | comments 0

J&J expects 10-plus new drug applications by 2017

(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...

Medications created 17 hours ago | popularity 5 / 5 (1) | comments 0

Experts favor US approval of Merck sleeping pill (Update)

An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.

Medications created May 22, 2013 | popularity not rated yet | comments 0

Glaxo, US partnering to develop new antibiotics

GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.

Medications created May 22, 2013 | popularity not rated yet | comments 0

Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine

The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...

Medications created May 22, 2013 | popularity not rated yet | comments 0


Engineered cytomegalovirus protects monkeys from HIV equivalent

(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...

Help at hand for people with schizophrenia

How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.

Scientists put bowel cancer under the microscope

Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.

New neuron formation could increase capacity for new learning, at the expense of old memories

New research presented today shows that formation of new neurons in the hippocampus - a brain region known for its importance in learning and remembering - could cause forgetting of old memories by causing a reorganization ...

Are there atheists in foxholes? Study says they're the minority

Ernie Pyle – an iconic war correspondent in World War II – reportedly said "There are no atheists in foxholes." A new joint study between two brothers at Cornell and Virginia Wesleyan found that only ...

Breathing exercises help veterans find peace after war, scholar says

(Medical Xpress)—Research by Stanford scholar Emma Seppala at the Center for Compassion and Altruism Research and Education found that post-traumatic stress disorder decreased in veterans who participated ...